Skip to content

Contact +44 (0) 20 7060 7474 email us

Company Information

Nycomed A/S: PharmaVitae Profile

 

Publication Date March 2009
Publisher Datamonitor
Product Type
Pages 117
ISBN Number not applicable
Product Code DAT01757

Price

£1,990.00
approximately: $3,013 | €2,221

pdf

Buy Now

print £3,060 ($4,633 | €3,415)

Buy Now

Order above formats by FAX

Order by Fax

Summary

Introduction

This analysis examines the historical and forecast performance for Nycomed in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

  • Benchmark Nycomed's performance against key rivals in the prescription pharmaceutical sector
  • Evaluate the consequences of the Altana acquisition and how the blockbuster pantoprazole has transformed Nycomed's operating performance
  • Assess the advantages of Nycomed's unique geographic and product development focus

Contents

  • CHAPTER 1 ABOUT THIS PROFILE
    • Executive summary
    • Quarterly news update
    • Company introduction
    • Company sales
    • Company financials
    • Key products and competitors
    • Data sourcing
    • Sales data
    • Analyst consensus
  • CHAPTER 2 EXECUTIVE SUMMARY
    • Key findings
    • Prescription pharmaceutical sales performance, 2001-13
    • Financial performance, 2001-13
    • Nycomed: PharmaVitae forecasts at a glance
    • Strategic insight
    • Nycomed's fortunes transformed by the reverse takeover of Altana Pharma
    • Generics threaten to undermine acquired blockbuster business model
    • M&A extends geographical reach to global scale
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
  • CHAPTER 3 QUARTERLY NEWS UPDATE
    • Quarterly sales update, Q408
    • Product developments
    • Deals and alliances
    • Product deals
    • Technology deals
    • M&A activity
    • Company announcements
    • Future product milestones
  • CHAPTER 4 COMPANY INTRODUCTION
    • Key findings
    • Background
    • Key corporate developments
    • M&A history
  • CHAPTER 5 COMPANY SALES
    • Key findings
    • Prescription pharmaceutical sales and growth rate analysis, 2001-13
    • Historical analysis
    • Forecast analysis
    • Product analysis
    • Product analysis, 2001-07
    • Product analysis, 2007-13
    • Growth Drivers
    • Growth Resistors
    • Therapy area analysis
    • Therapy area analysis, 2001-07
    • Therapy area analysis, 2007-13
    • Therapy area focus, 2001-13
    • Geographic analysis
    • Geographic analysis, 2001-07
    • Geographic analysis, 2007-13
    • Geographic focus, 2001-13
    • Launch/core/expiry analysis
    • Explanation of launch/core/expiry analysis
    • Launch analysis, 2007-13
    • Core analysis, 2007-13
    • Expiry analysis, 2007-13
    • Launch/core/expiry configuration, 2007-13
    • Molecule type analysis
    • Molecule type analysis, 2001-07
    • Molecule type analysis, 2007-13
    • Externalization analysis
    • Externalization analysis, 2001-07
    • Externalization analysis, 2007-13
  • CHAPTER 6 COMPANY FINANCIALS
    • Key findings
    • Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07
    • Financial statements, 2001-07
    • Profit and loss account, 2001-07
    • Balance sheet, 2001-07
    • Operating costs and profit analysis
    • Operating costs and profit analysis, 2001-07
    • Operating cost ratio and profit margin analysis, 2001-07
    • Operating cost ratio and profit margin analysis, 2007-13
    • Operating costs and profit analysis, 2007-13
    • Return on capital employed analysis
    • Capital employed analysis, 2001-07
    • Return on capital employed analysis, 2001-07
  • CHAPTER 7 KEY PRODUCTS AND COMPETITORS
    • Key findings
    • Overview
    • Gastroenterology
    • Pantoprazole
    • Overview
    • Sales forecast
    • Respiratory
    • Alvesco/Omnaris
    • Overview
    • Sales forecast
    • Urology & sexual health
    • Preotact
    • Overview
    • Sales forecast
    • Calcichew
    • Overview
    • Sales forecast
    • Endocrine, metabolic & genetic disorders
    • Actovegin
    • Overview
    • Sales forecast
  • CHAPTER 8 APPENDIX
    • R&D pipeline
    • References
    • Abbreviations
    • Exchange rates
  • List of Tables
    • Table 1: Nycomed: PharmaVitae forecasts at a glance
    • Table 2: Nycomed's financial transformation ($m), 2001-07
    • Table 3: Nycomed quarterly global sales update ($m), Q4 2008
    • Table 4: Nycomed key product developments, Q1 2008
    • Table 5: Nycomed product deals and alliances, Q1 2008
    • Table 6: Nycomed technology deals and alliances, Q1 2008
    • Table 7: Nycomed M&A activity, Q1 2008
    • Table 8: Nycomed company announcements, Q1 2008
    • Table 9: Nycomed future product milestones, 2008-10
    • Table 10: Nycomed product portfolio overview ($m), 2001-07
    • Table 11: Nycomed product portfolio overview ($m), 2007-13
    • Table 12: Nycomed product portfolio overview ($m), 2001-07
    • Table 13: Nycomed product portfolio overview ($m), 2007-13
    • Table 14: Nycomed portfolio overview by geographic region ($m), 2001-07
    • Table 15: Nycomed portfolio overview by geographic region ($m), 2007-13
    • Table 16: Nycomed launch portfolio overview ($m), 2007-13
    • Table 17: Nycomed core portfolio overview ($m), 2007-13
    • Table 18: Nycomed expiry portfolio overview ($m), 2007-13
    • Table 19: Nycomed portfolio overview by molecule type ($m), 2001-07
    • Table 20: Nycomed portfolio overview by molecule type ($m), 2007-13
    • Table 21: Nycomed product portfolio overview by source ($m), 2001-07
    • Table 22: Nycomed product portfolio overview by source ($m), 2007-13
    • Table 23: Total Nycomed sales by business unit ($m), 2001-07
    • Table 24: Nycomed profit and loss account ($m), 2001-07
    • Table 25: Nycomed balance sheet ($m), 2001-07
    • Table 26: Nycomed operating revenue/cost analysis ($m), 2001-07
    • Table 27: Nycomed operating cost ratio analysis (% of total revenues), 2001-07
    • Table 28: Nycomed operating cost ratio analysis (% of total revenues), 2007-13
    • Table 29: Nycomed operating revenue/cost analysis ($m), 2007-13
    • Table 30: Nycomed capital employed ($m), 2001-07
    • Table 31: Nycomed EBIT return on capital employed ($m), 2001-07
    • Table 32: Nycomed EBIT pre-tax return/capital employed driver analysis (%), 2001-07
    • Table 33: Key products overview
    • Table 34: Pantoprazole: overview
    • Table 35: Pantoprazole: sales forecast ($m), 2007-13
    • Table 36: Alvesco: overview
    • Table 37: Omnaris: overview
    • Table 38: Alvesco: sales forecast ($m), 2007-13
    • Table 39: Omnaris: sales forecast ($m), 2007-13
    • Table 40: Preotact: overview
    • Table 41: Preotact: sales forecast ($m), 2007-13
    • Table 42: Calcichew: overview
    • Table 43: Calchew: sales forecast ($m), 2007-13
    • Table 44: Actovegin: overview
    • Table 45: Actovegin: sales forecast ($m), 2007-13
    • Table 46: Nycomed's R&D pipeline (Phase I-registration)
    • Table 47: Exchange rates, 2007
  • List of Figures
    • Figure 1: Nycomed prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
    • Figure 2: Nycomed's financial performance ($m), 2001-13
    • Figure 3: Nycomed's operating performance transformed over 2005-07
    • Figure 4: Pantoprazole expiry prevents profit expanion
    • Figure 5: Nycomed sales by geography ($m), 2006
    • Figure 6: Nycomed sales by geography ($m), 2007
    • Figure 7: Nycomed SWOT analysis
    • Figure 8: Top 10 product sales ($m), forecast vs. actual, 2008
    • Figure 9: Nycomed prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
    • Figure 10: Nycomed key sales growth driver & resistors ($m), 2001-07
    • Figure 11: Nycomed key sales growth drivers & resistors ($m), 2007-13
    • Figure 12: Nycomed prescription pharmaceutical sales by therapy area ($m), 2001-13
    • Figure 13: Nycomed prescription pharma sales by therapy area (% of total), 2001-13
    • Figure 14: Nycomed prescription pharmaceutical sales by geographic region ($m), 2001-13
    • Figure 15: Nycomed growth drivers and resistors by geographic region ($m), 2001-07
    • Figure 16: Nycomed drivers and resistors by geographic region ($m), 2007-13
    • Figure 17: Nycomed prescription pharmaceutical sales by geographic region (% of total), 2001-13
    • Figure 18: Nycomed launch/core/expiry configuration ($m), 2007-13
    • Figure 19: Nycomed prescription pharmaceutical sales by molecule type ($m), 2001-13
    • Figure 20: Nycomed growth drivers and resistors by molecule type ($m), 2007-13
    • Figure 21: Nycomed prescription pharmaceutical sales by source ($m), 2001-13
    • Figure 22: Nycomed growth drivers and resistors by source ($m), 2001-07
    • Figure 23: Nycomed growth drivers and resistors by source ($m), 2007-13
    • Figure 24: Nycomed operating revenue/cost analysis ($m), 2001-13
    • Figure 25: Nycomed operating cost ratio analysis (% of total revenues), 2001-13
    • Figure 26: Nycomed return on capital employed, EBIT margin and capital turnover, 2001-07
    • Figure 27: Return on capital employed formula